In this episode of the a16z Podcast, we take a deep dive into the world of drug development—specifically "undruggable drugs": a category of protein, protein family or even piece of RNA that’s so difficult to target that many researchers don’t even want to touch it.  Jay Bradner, President of the Novartis Institute for BioMedical Research, shares with a16z General Partners Jorge Conde and Vijay Pande, and a16z's Hanne Tidnam, all the new tools, technologies and breakthroughs which are causing the science of therapeutics to explode in some of these areas where it's been incredibly difficult (even impossible) in the past. From molecular glues to cell and gene therapies, Bradner shares the behind-the-scenes science stories of what it really takes to make a new drug that shatters the category of an "undruggable" target. 

The Chief Security Officer (CSO/CISO) used to manage on-premise servers, now the information they have to secure has migrated to the cloud. As the responsibility of CSOs has expanded, the role has moved from technical IT to the boardroom. How do the best CSOs prepare for and respond to a crisis, from redteaming to comms? What responsibility should cloud & SaaS vendors, not to mention the government, have in security and data breaches?  And how is the role going to evolve in the next five years?  At our a16z Innovation Summit last year, we sat down with two security leaders whose career has evolved as the role has – Joe Sullivan, former CSO at Uber and Facebook, now at Cloudflare and Joel de la Garza, current security partner at a16z, formerly CISO at Box.